[HTML][HTML] Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034
MJ van den Bent, AA Brandes, R Rampling… - Journal of Clinical …, 2009 - ncbi.nlm.nih.gov
MJ van den Bent, AA Brandes, R Rampling, MCM Kouwenhoven, JM Kros, AF Carpentier…
Journal of Clinical Oncology, 2009•ncbi.nlm.nih.govPurpose Approximately 50% of glioblastomas (GBMs) are characterized by overexpression
of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In
approximately 25% of instances, constitutively activated EGFR mutants are present. These
observations make EGFR-inhibiting drugs a logical approach for trials in recurrent GBM.
of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In
approximately 25% of instances, constitutively activated EGFR mutants are present. These
observations make EGFR-inhibiting drugs a logical approach for trials in recurrent GBM.
Abstract
Purpose
Approximately 50% of glioblastomas (GBMs) are characterized by overexpression of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In approximately 25% of instances, constitutively activated EGFR mutants are present. These observations make EGFR-inhibiting drugs a logical approach for trials in recurrent GBM.
ncbi.nlm.nih.gov